Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
Week ahead: 5 IPOs set to price during the week of August 10
Analyst IPO Market Commentary
It's the final push for US IPOs before a four-week lull that should end in mid-September.
Five IPOs are on the
this week, plus two blank check companies. Sickle cell biotech
Global Blood Therapeutics
could attract investor attention, while investment bank
boasts a dominant position in mid-cap M&A. Our
Even without the annual late-summer pause in the IPO market, activity might have slowed down due to poor returns. In the past two weeks, five companies have postponed and more than half of the IPOs trade below the offer price. However, the IPO pipeline contains 115 companies, including a recent uptick in billion-dollar IPO filings, which indicates an active fourth quarter. With Labor Day four weeks away, the number of emerging-growth IPOs that file this week should also signal the IPO market's health.
Sick of sickle cell disease?
Global Blood Therapeutics
), a relatively large biotech with promising results and prominent backers, has the most "pop-potential" out of any IPO this week. The company has received $100 million from Third Rock, Fidelity, Wellington, RA Capital and Deerfield. Larger biotechs have historically outperformed, and Global Blood has targeted a market cap of over $500 million. The biotech has successfully dosed six patients, but it could run into trouble if competitor bluebird bio (Nasdaq: BLUE) successfully develops its one-shot cure for sickle cell disease. In the past three years, Morgan Stanley has been a joint bookrunner on 10 biotech IPOs (average return of +140%) and Goldman Sachs has underwritten 8 (+215%).
An investment in an investment bank
) expects to raise $300 million at a market cap of $1.5 billion, meaning it could raise more capital at a larger valuation than the week's other four IPOs combined. As the market leader in mid-cap M&A, Houlihan has seen its earnings soar thanks to a boom in US M&A activity. In addition, its low non-comp ratio suggests superior operating efficiencies. Close peer Moelis & Company (
) gained 5% on its IPO in April 2014, and now trades 20% above the offer price. The selling shareholders, including Orix, executives and employees, will float the entire offering and receive an additional $270 million dividend while retaining 98% voting control.
Two microcap IPOs: Specialty insurance and interactive projectors
) plans to raise $55 million, roughly half of its proposed market cap. Backed by CEO James Petcoff and Strength Capital Partners, the specialty property and casualty insurer has tripled its revenue since 2012, booking $61 million in 2014. Most insurance peers have sold off in the past month. Liquidated in 2013 and bought by Vert Capital,
) expects that expanded school budgets should drive higher sales of its specialty projectors and other classroom materials.
IPO or bust: Breast implant company makes second attempt
) has come back from its predecessors' bankruptcy as a major breast implant maker in Europe and South America, particularly Brazil. The company had been on the IPO calendar for last week, meaning investors may be pushing for a reduction in its proposed valuation despite the relatively strong performance of US peer and 2014 IPO Sientra (
; +57% from the offer price).
Renaissance Capital's IPO Calendar - Week of August 10, 2015
Top 2 bookrunners
Los Angeles, CA
$22 - $24
BofA Merrill Lynch
Mid-cap focused independent investment bank.
Global Blood Therapeutics
South San Francisco, CA
$16 - $18
Early-stage biotech developing a small molecule therapy for sickle cell disease.
$13 - $15
BofA Merrill Lynch
Provider of silicone breast implants in Latin America and EMEA.
$11 - $13
BMO Capital Markets
Specialty property insurance provider led by executives from North Pointe.
$10 - $12
Manufactures interactive projectors and other classroom materials.
Find out why institutional investors rely on Renaissance Capital's
for these IPOs.
Follow us on Twitter (
) for IPO news as it happens and
register for our updates
on the IPO market.
IPO pipeline update: 3 LBO'd companies including Neiman Marcus
More billion-dollar IPOs join the
as Neiman Marcus (
) refiled for an initial public offering that could come near the end of September at the earliest. After ten years of private equity ownership, the company has achieved over $5 billion in annual sales. CD&R's Mauser Group (
), which makes industrial chemical containers, could raise $300 million. CPI Card Group (
), owned by Tricor Pacific Capital, is the largest maker of credit and debit cards in the US.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. The Renaissance IPO Index has traded up 1.8% year-to-date, compared to 0.9% for the S&P 500. Renaissance Capital's
(NYSE: IPO) tracks the index, and
top ETF holdings
include Alibaba (
), Hilton Worldwide (
) and Twitter (
). The Renaissance International IPO Index has traded up over 4.6% year-to-date, compared to less than 1.9% for the ACWX. Renaissance Capital’s International
(NYSE: IPOS) tracks the index, and
top ETF Holdings
include Altice and Recruit Holdings.
To find out if this is the best ETF for you, visit our
IPO Investing page
Keywords / Tickers:
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.